Literature DB >> 30349972

[The role of molecular imaging (PET-CT) in the diagnostic and treatment pf prostate cancer].

Siroos Mirzaei1, Peter Knoll2, Shahin Zandieh3.   

Abstract

Prostate cancer is the most frequent cancer type in men in industrialized countries. In case of biochemical recurrent disease of prostate cancer is molecular imaging with PET-CT or PET-MRI a very promising modality for the detection of local recurrence, lymph node involvement or distant metastasis. Of the so far implemented radiopharmaceuticals the radioactive labeled PSMA ligands (i. e. Ga-68 PSMA) have prevailed. There are also in the meanwhile treatment approaches with PSMA ligands (i. e. Lu-177 PSMA) in case of metastatic disease.

Entities:  

Keywords:  PET; PSMA; Prostate cancer

Mesh：

Substances：

Year:  2018        PMID： 30349972     DOI： 10.1007/s10354-018-0668-5

Source DB:  PubMed          Journal:  Wien Med Wochenschr        ISSN： 0043-5341


  7 in total

1.  Clinical performance of 68Ga-PSMA-11 PET/MRI for the detection of recurrent prostate cancer following radical prostatectomy.

Authors:  Benedikt Kranzbühler; Hannes Nagel; Anton S Becker; Julian Müller; Martin Huellner; Paul Stolzmann; Urs Muehlematter; Matthias Guckenberger; Philipp A Kaufmann; Daniel Eberli; Irene A Burger
Journal:  Eur J Nucl Med Mol Imaging       Date:  2017-10-14       Impact factor: 9.236

2.  Prospective comparison of whole-body bone SPECT and sodium 18F-fluoride PET in the detection of bone metastases from breast cancer.

Authors:  Gad Abikhzer; Saher Srour; Georgeta Fried; Karen Drumea; Ela Kozlener; Alex Frenkel; Ora Israel; Ignac Fogelman; Olga Kagna
Journal:  Nucl Med Commun       Date:  2016-11       Impact factor: 1.690

3.  Evaluation of Hybrid ⁶⁸Ga-PSMA Ligand PET/CT in 248 Patients with Biochemical Recurrence After Radical Prostatectomy.

Authors:  Matthias Eiber; Tobias Maurer; Michael Souvatzoglou; Ambros J Beer; Alexander Ruffani; Bernhard Haller; Frank-Philipp Graner; Hubert Kübler; Uwe Haberkorn; Michael Eisenhut; Hans-Jürgen Wester; Jürgen E Gschwend; Markus Schwaiger
Journal:  J Nucl Med       Date:  2015-03-19       Impact factor: 10.057

4.  [44Sc]Sc-PSMA-617 Biodistribution and Dosimetry in Patients With Metastatic Castration-Resistant Prostate Carcinoma.

Authors:  Ambreen Khawar; Elisabeth Eppard; Jean Phlippe Sinnes; Frank Roesch; Hojjat Ahmadzadehfar; Stefan Kürpig; Michael Meisenheimer; Florian C Gaertner; Markus Essler; Ralph A Bundschuh
Journal:  Clin Nucl Med       Date:  2018-05       Impact factor: 7.794

5.  64Cu-PSMA-617 PET/CT Imaging of Prostate Adenocarcinoma: First In-Human Studies.

Authors:  Bernhard Grubmüller; Richard P Baum; Enza Capasso; Aviral Singh; Yasaman Ahmadi; Peter Knoll; Andreas Floth; Sergio Righi; Shahin Zandieh; Carlo Meleddu; Shahrokh F Shariat; Hans Christoph Klingler; Siroos Mirzaei
Journal:  Cancer Biother Radiopharm       Date:  2016-10-07       Impact factor: 3.099

Review 6.  Current status of theranostics in prostate cancer.

Authors:  Irene Virgolini; Clemens Decristoforo; Alexander Haug; Stefano Fanti; Christian Uprimny
Journal:  Eur J Nucl Med Mol Imaging       Date:  2017-12-28       Impact factor: 9.236

7.  Assessment of Bone Metastases in Patients with Prostate Cancer-A Comparison between 99mTc-Bone-Scintigraphy and [68Ga]Ga-PSMA PET/CT.

Authors:  Lena Thomas; Caroline Balmus; Hojjat Ahmadzadehfar; Markus Essler; Holger Strunk; Ralph A Bundschuh
Journal:  Pharmaceuticals (Basel)       Date:  2017-07-31
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.